Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kavita, Juneja"'
Autor:
Rita Humeniuk, Kavita Juneja, Shuguang Chen, Scott Ellis, Olena Anoshchenko, Deqing Xiao, Aaron Share, Matthew Johnston, Santosh Davies, Adam DeZure, Joe Llewellyn, Anu Osinusi, Helen Winter, Sandhya Girish, Ramesh Palaparthy, Mark Dresser
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 11, Pp 2276-2288 (2023)
Abstract Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS
Externí odkaz:
https://doaj.org/article/ab437c86ec334aa9a0a440c7bdc247ab
Autor:
Rebecca N. Bauer, Anastasia Teterina, Haridha Shivram, Jacqueline McBride, Carrie M. Rosenberger, Fang Cai, Min Bao, Larry Tsai, Oliver Gordon, Ivan T. Lee, Jeffrey J. Wallin, Danielle Porter, Kavita Juneja, Gregory Camus, Ivan O. Rosas, Steffen Wildum
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 6, Pp 1049-1062 (2023)
Abstract Observational studies have identified the potential prognostic value for severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) viral load and anti‐SARS‐CoV‐2 antibodies in coronavirus disease 2019 (COVID‐19). However, vi
Externí odkaz:
https://doaj.org/article/82e498d85ae64400857694f98dd85b56
Autor:
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 4, Pp 1189-1203 (2023)
Abstract Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we r
Externí odkaz:
https://doaj.org/article/92c2e56adfd9476080f60f8837813ee7
Autor:
David Z. Pan, Pamela M. Odorizzi, Andre Schoenichen, Mazin Abdelghany, Shuguang Chen, Anu Osinusi, Scott D. Patterson, Bryan Downie, Kavita Juneja, Jeffrey J. Wallin
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-6 (2023)
Pan et al. determine the impact of the antiviral remdesivir (RDV) on biomarkers associated with clinical outcomes, within a randomized, double-blind, placebo-controlled phase 3 study (PINETREE). They demonstrate that RDV-treated patients have an acce
Externí odkaz:
https://doaj.org/article/8ae67f1cda5e4070bf72742899d454ad
Autor:
Joy Y. Feng, Venice Du Pont, Darius Babusis, Calvin J. Gordon, Egor P. Tchesnokov, Jason K. Perry, Vincent Duong, Arya Vijjapurapu, Xiaofeng Zhao, Julie Chan, Cal Cohen, Kavita Juneja, Tomas Cihlar, Matthias Götte, John P. Bilello
Publikováno v:
Molecules, Vol 27, Iss 13, p 4212 (2022)
The urgent response to the COVID-19 pandemic required accelerated evaluation of many approved drugs as potential antiviral agents against the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Using cell-based, biochemi
Externí odkaz:
https://doaj.org/article/8efa8d1cc25f4a15b4af0c4caa0f1353
Autor:
Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert, Robin L Dewar, Sylvain Laverdure, Helene Highbarger, Perrine Lallemand, Meei-Li Huang, Keith R Jerome, Reigran Sampoleo, Margaret Mills, Danielle P Porter, Kavita Juneja, Alexander L Greninger, H Clifford Lane, John H Beigel, Lori E Dodd
Publikováno v:
Open Forum Infectious Diseases. 9
Background ACTT-1 demonstrated clinical efficacy of remdesivir (RDV) in hospitalized patients with COVID-19; subgroup analyses suggested those most likely to benefit presented with milder clinical illness. To further clarify what subsets of hospitali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a304fc78b45580c316a09894e0187949
https://doi.org/10.1093/ofid/ofac492.050
https://doi.org/10.1093/ofid/ofac492.050
Publikováno v:
Antimicrobial Agents and Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4888178296c3a59d26688a8a37a4729
http://europepmc.org/articles/PMC8097414
http://europepmc.org/articles/PMC8097414
Autor:
Eun Young Lee, Lauren Dau, Diogo Ferrinho, Anu Osinusi, Diana M. Brainard, ChenYu Wang, Tram Tran, Kavita Juneja, Anand P. Chokkalingam
Publikováno v:
Open Forum Infectious Diseases
Background COVID-19 has spread rapidly: from the first case in Dec 2019, the declaration of a global pandemic in Mar 2020, to Jun 18, 2020 with >8 M confirmed cases and >400,000 deaths worldwide. Throughout this rapid spread, Gilead has focused on co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecac9580c8f3f1bddeb002944f082d40
Autor:
Ragini, Kulkarni, Sanjay, Chauhan, Beena, Joshi, Kusum, Balsaraf, Ravindra, Chaudhari, Gauri, Donde, Kavita, Juneja
Publikováno v:
Indian Journal of Medical Research. 156:191
In the current health system, cash incentives are given to accredited social health activists for referring women to public health facilities for specific maternal and child health services, however many reproductive health problems are not included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d583ac5dd4bb3edaf011b77e5691d6
https://doi.org/10.4103/ijmr.ijmr_1827_20
https://doi.org/10.4103/ijmr.ijmr_1827_20
Autor:
Mazen Noureddin, Amber L. Martin, Samantha Martel, Robert Myers, Angela Nitka, Meghna Mehta, Kavita Juneja, Arun Sanyal
Publikováno v:
Journal of Hepatology. 73:S424
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a54e7a2952ff49af233f1d1f07926e6f
https://doi.org/10.1016/s0168-8278(20)31331-3
https://doi.org/10.1016/s0168-8278(20)31331-3